[8-K] Coherus Oncology, Inc. Reports Material Event

Rhea-AI Filing Summary

Amended Form 4 filing: On 06/16/2025, Tracy Ward, Senior Vice President & Controller of BlackSky Technology Inc. (BKSY), exercised employee stock options (code M) and acquired 2,554 Class A common shares at an exercise price of $11.59 per share. Following the transaction, Ward now directly owns 45,107 shares of BKSY.

This Form 4/A corrects the share amounts originally reported on 06/25/2025, ensuring Section 16 compliance. The event represents an internal conversion of derivative securities rather than an open-market purchase or sale, so it does not affect outstanding share count, company cash flow, or near-term earnings.

While the additional holdings are modest relative to BlackSky’s public float, the exercise marginally increases insider ownership and may be viewed as a signal of management’s confidence. The prompt amendment also supports governance transparency by rectifying prior disclosure errors.

Insights

Financial Analyst

TL;DR: Minor option exercise, 2,554 shares; negligible valuation impact.

The transaction adds roughly US$29.6 k worth of stock (2,554 × $11.59) to the insider’s holdings—immaterial against BlackSky’s market capitalisation. No cash changes hands at the corporate level, and dilution is de minimis. From a market-moving perspective, the filing is neutral; however, a gradual uptick in insider ownership can support sentiment if repeated by multiple executives.

Corporate Governance Expert

TL;DR: Corrected Form 4 enhances disclosure accuracy; governance neutral.

The amendment rectifies previously misstated share counts, mitigating potential Section 16 non-compliance risk. Accurate insider reporting is critical for investor trust and regulatory adherence. Although the initial error suggests a minor lapse in internal controls, prompt correction limits reputational exposure. Overall governance impact is neutral, with a slight positive tilt toward transparency.

0001512762false00015127622025-06-302025-06-30

​​UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549​

​FORM 8-K​

​CURRENT REPORTPursuant to Section 13 or 15(d)of the Securities Exchange Act of 1934​Date of Report (Date of earliest event reported): June 30, 2025​

​COHERUS ONCOLOGY, INC.(Exact name of registrant as specified in its charter)​​

Delaware		001-36721		27-3615821
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification Number)

​333 Twin Dolphin Drive, Suite 600Redwood City, CA 94065(Address of principal executive offices, including Zip Code)​Registrant’s telephone number, including area code: (650) 649-3530​N/A(Former name or former address, if changed since last report)​Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:​

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
​	​
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
​	​
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
​	​
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​Securities registered pursuant to Section 12(b) of the Act:​

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		CHRS		The Nasdaq Global Market

​Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).​Emerging growth company  ☐​If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐​​

​

Item 3.01.Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing​On June 30, 2025, Coherus Oncology, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq Listing Rule 5450(a)(1).The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Market. ​In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 calendar days, or until December 29, 2025 (the “Compliance Date”), to regain compliance with the minimum bid price requirement by having shares of the Company’s common stock maintain a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days before the Compliance Date. If the Company’s common stock does not achieve compliance by the Compliance Date, the Company may be eligible for an additional 180 calendar day period to regain compliance. To qualify for the second compliance period, the Company would be required to transfer its listing to the Nasdaq Capital Market and meet the continued listing requirement for market value of publicly held shares and all other applicable initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and would need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Staff that the Company would not be able to cure the deficiency, or if the Company is otherwise not eligible for the second compliance period, and the Company does not regain compliance by the Compliance Date, the Staff will provide written notification that the Company’s common stock is subject to delisting. At that time, the Company may appeal the delisting determination to a hearings panel pursuant to the procedures set forth in the applicable Nasdaq listing rules. However, there can be no assurance that, if the Company receives a delisting notice and appeals the delisting determination by Nasdaq to the panel, such appeal would be successful.​The Company intends to actively monitor the closing bid price of its common stock between now and the Compliance Date and, as appropriate, will evaluate available options to resolve the deficiency and regain compliance with the Nasdaq minimum bid price requirement.​​​​​​​​​​

SIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.​

​	​	​	​
Date: July 3, 2025		COHERUS ONCOLOGY, INC.
​	​	​	​
​	​	By:	/s/ Dennis M. Lanfear
​	​	Name:	Dennis M. Lanfear
​	​	Title:	Chief Executive Officer

​​​​